Symbols / JAGX
JAGX Chart
About
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.57M |
| Enterprise Value | 31.95M | Income | -40.29M | Sales | 11.79M |
| Book/sh | 0.85 | Cash/sh | 0.94 | Dividend Yield | — |
| Payout | 0.00% | Employees | 49 | IPO | — |
| P/E | — | Forward P/E | -0.11 | PEG | — |
| P/S | 0.22 | P/B | 0.72 | P/C | — |
| EV/EBITDA | -1.03 | EV/Sales | 2.71 | Quick Ratio | 0.14 |
| Current Ratio | 0.81 | Debt/Eq | 731.82 | LT Debt/Eq | — |
| EPS (ttm) | -2.58 | EPS next Y | -5.68 | EPS Growth | — |
| Revenue Growth | -0.80% | Earnings | 2026-03-31 | ROA | -38.01% |
| ROE | -4.12% | ROIC | — | Gross Margin | 81.92% |
| Oper. Margin | -234.77% | Profit Margin | 0.00% | Shs Outstand | 4.18M |
| Shs Float | 2.61M | Short Float | 14.71% | Short Ratio | 0.05 |
| Short Interest | — | 52W High | 25.75 | 52W Low | 0.56 |
| Beta | 0.12 | Avg Volume | 3.82M | Volume | 122.25K |
| Target Price | $7.50 | Recom | Buy | Prev Close | $0.63 |
| Price | $0.62 | Change | -2.44% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.50
Mean price target
2. Current target
$0.62
Latest analyst target
3. DCF / Fair value
$-65.44
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.62
Low
$7.50
High
$7.50
Mean
$7.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-05-19 | init | First Berlin | — → Buy | $60 |
- Jaguar trial cuts children’s IV support needs by up to 37% - Stock Titan hu, 22 Jan 2026 08
- Jaguar Health stock swings as Future Pak licensing deal dangles $38 million — here’s what traders see - TechStock² Mon, 12 Jan 2026 08
- Can JAGX stock double in the next year - 2025 Top Gainers & Stock Portfolio Risk Control - mfd.ru Sat, 14 Feb 2026 23
- Recent Developments in Jaguar Health - StocksToTrade Sun, 18 Jan 2026 08
- Slammed 27% Jaguar Health, Inc. (NASDAQ:JAGX) Screens Well Here But There Might Be A Catch - simplywall.st Fri, 29 Aug 2025 07
- Jaguar Health Completes Private Placement Deal - Yahoo Finance Sun, 21 Sep 2025 07
- Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): BUY - TradingView hu, 12 Feb 2026 14
- Healthcare summit talk: Jaguar Health's Jan. 15 virtual investor update - Stock Titan Wed, 14 Jan 2026 08
- JAGX stock touches 52-week low at $0.21 amid sharp annual decline - Investing.com Fri, 21 Mar 2025 07
- 3 Penny Stocks to Watch Now, 1/19/26 - TipRanks Mon, 19 Jan 2026 08
- The Surge In Jaguar Health Stock: What's Happening Now? - Benzinga Fri, 16 Jan 2026 08
- Will JAGX stock benefit from automation - Earnings Growth Report & Technical Buy Zone Confirmations - mfd.ru Sat, 14 Feb 2026 17
- Jaguar Health Signs Securities Purchase Agreements With Accredited Investors - TradingView Mon, 12 Jan 2026 08
- Jaguar Health (NASDAQ: JAGX) clears all special meeting items, notes MVID trial progress - Stock Titan Mon, 08 Dec 2025 08
- Is JAGX a top pick in the sector - July 2025 Fed Impact & Stock Market Timing Techniques - mfd.ru Sun, 15 Feb 2026 19
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 11740 | — | — | Stock Award(Grant) at price 0.00 per share. | WOLIN JONATHAN S | General Counsel | — | 2025-12-11 00:00:00 | D |
| 1 | 5870 | — | — | Stock Award(Grant) at price 0.00 per share. | JAYASURIYA ANULA | Director | — | 2025-12-11 00:00:00 | D |
| 2 | 11740 | — | — | Stock Award(Grant) at price 0.00 per share. | CHATURVEDI PRAVIN R | Officer | — | 2025-12-11 00:00:00 | D |
| 3 | 6363 | — | — | Stock Award(Grant) at price 0.00 per share. | BOCHNOWSKI JAMES J. | Director | — | 2025-12-11 00:00:00 | D |
| 4 | 11740 | — | — | Stock Award(Grant) at price 0.00 per share. | KING STEVEN R. PH.D. | Officer | — | 2025-12-11 00:00:00 | D |
| 5 | 28592 | — | — | Stock Award(Grant) at price 0.00 per share. | CONTE LISA A. | Chief Executive Officer | — | 2025-12-11 00:00:00 | D |
| 6 | 7377 | — | — | Stock Award(Grant) at price 0.00 per share. | SIEGEL JONATHAN B | Director | — | 2025-12-11 00:00:00 | D |
| 7 | 11740 | — | — | Stock Award(Grant) at price 0.00 per share. | LIZAK CAROL R. | Chief Financial Officer | — | 2025-12-11 00:00:00 | D |
| 8 | 1 | nan | — | — | KING STEVEN R. PH.D. | Officer | — | 2025-05-16 00:00:00 | D |
| 9 | 2 | nan | — | — | CONTE LISA A. | Chief Executive Officer | — | 2025-05-16 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -28.42M | -31.33M | -31.17M | -39.66M |
| TotalUnusualItems | -8.24M | -1.80M | -2.21M | -2.71M |
| TotalUnusualItemsExcludingGoodwill | -8.24M | -1.80M | -2.21M | -2.71M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -38.49M | -41.30M | -47.45M | -52.59M |
| ReconciledDepreciation | 2.36M | 2.39M | 2.29M | 1.81M |
| ReconciledCostOfRevenue | 1.96M | 2.04M | 2.02M | 2.33M |
| EBITDA | -36.66M | -33.13M | -33.38M | -42.37M |
| EBIT | -39.02M | -35.52M | -35.67M | -44.18M |
| NetInterestIncome | -231.00K | -6.38M | -12.72M | -10.05M |
| InterestExpense | 231.00K | 6.38M | 12.72M | 8.42M |
| NormalizedIncome | -30.25M | -39.50M | -45.25M | -49.89M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -38.49M | -41.30M | -47.45M | -52.59M |
| TotalExpenses | 42.52M | 43.68M | 46.37M | 43.41M |
| RentExpenseSupplemental | 817.00K | 877.00K | 629.00K | 282.00K |
| TotalOperatingIncomeAsReported | -30.83M | -34.29M | -34.41M | -40.71M |
| DilutedAverageShares | 294.53K | 15.42K | 1.46K | 430.00 |
| BasicAverageShares | 294.53K | 15.42K | 1.46K | 430.00 |
| DilutedEPS | -130.69 | -2.68K | -32.61K | -122.31K |
| BasicEPS | -130.69 | -2.68K | -32.61K | -122.31K |
| DilutedNIAvailtoComStockholders | -38.49M | -41.30M | -47.45M | -52.59M |
| NetIncomeCommonStockholders | -38.49M | -41.30M | -47.45M | -52.59M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -38.49M | -41.30M | -47.45M | -52.59M |
| MinorityInterests | 759.00K | 601.00K | 941.00K | 5.00K |
| NetIncomeIncludingNoncontrollingInterests | -39.25M | -41.90M | -48.40M | -52.60M |
| NetIncomeContinuousOperations | -39.25M | -41.90M | -48.40M | -52.60M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -39.25M | -41.90M | -48.40M | -52.60M |
| OtherIncomeExpense | -8.19M | -1.60M | -1.26M | -3.47M |
| OtherNonOperatingIncomeExpenses | 51.00K | 200.00K | 950.00K | -765.00K |
| SpecialIncomeCharges | 1.25M | 3.33M | -2.19M | -753.00K |
| OtherSpecialCharges | -1.25M | -3.70M | 2.19M | 753.00K |
| ImpairmentOfCapitalAssets | 0.00 | 371.00K | 0.00 | |
| GainOnSaleOfSecurity | -9.48M | -5.12M | -20.00K | -1.95M |
| NetNonOperatingInterestIncomeExpense | -231.00K | -6.38M | -12.72M | -10.05M |
| TotalOtherFinanceCost | 1.63M | |||
| InterestExpenseNonOperating | 231.00K | 6.38M | 12.72M | 8.42M |
| OperatingIncome | -30.83M | -33.92M | -34.41M | -39.07M |
| OperatingExpense | 40.56M | 41.64M | 44.35M | 41.08M |
| ResearchAndDevelopment | 16.54M | 18.60M | 17.65M | 15.08M |
| SellingGeneralAndAdministration | 24.02M | 23.05M | 26.70M | 26.00M |
| SellingAndMarketingExpense | 4.09M | 3.28M | 5.16M | 8.89M |
| GeneralAndAdministrativeExpense | 19.93M | 19.77M | 21.55M | 17.10M |
| OtherGandA | 10.01M | 9.66M | 9.87M | 11.10M |
| RentAndLandingFees | 817.00K | 877.00K | 629.00K | 282.00K |
| SalariesAndWages | 9.10M | 9.23M | 11.05M | 5.73M |
| GrossProfit | 9.73M | 7.72M | 9.94M | 2.00M |
| CostOfRevenue | 1.96M | 2.04M | 2.02M | 2.33M |
| TotalRevenue | 11.69M | 9.76M | 11.96M | 4.33M |
| OperatingRevenue | 15.58M | 13.61M | 15.02M | 15.72M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 528.44K | 48.94K | 1.46K | 430.00 |
| ShareIssued | 528.44K | 48.94K | 1.46K | 430.00 |
| NetDebt | 27.54M | 29.39M | 28.16M | 11.15M |
| TotalDebt | 36.53M | 37.09M | 34.84M | 29.36M |
| TangibleBookValue | -11.19M | -15.15M | -23.10M | -11.04M |
| InvestedCapital | 42.83M | 40.82M | 32.97M | 39.82M |
| WorkingCapital | 12.49M | 13.98M | -8.02M | 12.96M |
| NetTangibleAssets | -11.19M | -15.15M | -23.10M | -11.04M |
| CapitalLeaseObligations | 985.00K | 1.23M | 1.21M | 1.16M |
| CommonStockEquity | 7.29M | 4.96M | -657.00K | 11.61M |
| TotalCapitalization | 30.79M | 35.95M | 17.09M | 36.63M |
| TotalEquityGrossMinorityInterest | 6.49M | 4.90M | -1.36M | 11.85M |
| MinorityInterest | -791.00K | -64.00K | -699.00K | 242.00K |
| StockholdersEquity | 7.29M | 4.96M | -657.00K | 11.61M |
| GainsLossesNotAffectingRetainedEarnings | -467.00K | -652.00K | -680.00K | 0.00 |
| OtherEquityAdjustments | -467.00K | -652.00K | -680.00K | |
| RetainedEarnings | -346.48M | -308.25M | -266.95M | -219.49M |
| AdditionalPaidInCapital | 354.23M | 313.86M | 266.97M | 231.10M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 46.93M | 45.87M | 48.81M | 41.41M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 27.23M | 31.88M | 18.47M | 25.94M |
| PreferredSecuritiesOutsideStockEquity | 2.48M | 0.00 | ||
| NonCurrentDeferredLiabilities | 553.00K | 0.00 | ||
| NonCurrentDeferredRevenue | 553.00K | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 24.19M | 31.88M | 18.47M | 25.94M |
| LongTermCapitalLeaseObligation | 686.00K | 886.00K | 725.00K | 919.00K |
| LongTermDebt | 23.50M | 30.99M | 17.74M | 25.02M |
| CurrentLiabilities | 19.70M | 13.99M | 30.34M | 15.47M |
| OtherCurrentLiabilities | 1.00K | |||
| CurrentDeferredLiabilities | 170.00K | 0.00 | ||
| CurrentDeferredRevenue | 170.00K | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 12.34M | 5.21M | 16.37M | 3.42M |
| CurrentCapitalLeaseObligation | 299.00K | 348.00K | 483.00K | 240.00K |
| CurrentDebt | 12.04M | 4.87M | 15.88M | 3.18M |
| OtherCurrentBorrowings | 12.04M | 4.87M | 15.88M | 3.18M |
| PayablesAndAccruedExpenses | 7.20M | 8.77M | 13.97M | 12.05M |
| CurrentAccruedExpenses | 1.80M | 3.51M | 7.58M | 6.61M |
| InterestPayable | 4.00K | 719.00K | 5.49M | 3.46M |
| Payables | 5.40M | 5.27M | 6.39M | 5.44M |
| TotalTaxPayable | 114.00K | 292.00K | 585.00K | 510.00K |
| AccountsPayable | 5.29M | 4.97M | 5.81M | 4.93M |
| TotalAssets | 53.42M | 50.76M | 47.45M | 53.27M |
| TotalNonCurrentAssets | 21.23M | 22.80M | 25.13M | 24.83M |
| OtherNonCurrentAssets | 1.35M | 1.01M | 995.00K | 446.00K |
| GoodwillAndOtherIntangibleAssets | 18.48M | 20.12M | 22.44M | 22.65M |
| OtherIntangibleAssets | 18.48M | 20.12M | 22.44M | 22.65M |
| NetPPE | 1.40M | 1.67M | 1.70M | 1.73M |
| AccumulatedDepreciation | -513.00K | -465.00K | -404.00K | -298.00K |
| GrossPPE | 1.91M | 2.14M | 2.10M | 2.03M |
| OtherProperties | 477.00K | 477.00K | 1.62M | 1.57M |
| MachineryFurnitureEquipment | 221.00K | 282.00K | 88.00K | 63.00K |
| BuildingsAndImprovements | 819.00K | 982.00K | ||
| LandAndImprovements | 396.00K | 396.00K | 396.00K | 396.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 32.20M | 27.96M | 22.32M | 28.43M |
| OtherCurrentAssets | 12.20M | 10.12M | 7.36M | 4.34M |
| PrepaidAssets | 4.34M | |||
| Inventory | 10.35M | 9.19M | 7.02M | 4.90M |
| FinishedGoods | 1.09M | 615.00K | 1.32M | 892.00K |
| WorkInProcess | 7.41M | 6.52M | 3.60M | 2.76M |
| RawMaterials | 1.85M | 2.06M | 2.10M | 1.25M |
| Receivables | 1.65M | 2.18M | 2.47M | 2.14M |
| OtherReceivables | 120.00K | 217.00K | 588.00K | 435.00K |
| AccountsReceivable | 1.53M | 1.97M | 1.88M | 1.71M |
| CashCashEquivalentsAndShortTermInvestments | 8.00M | 6.47M | 5.47M | 17.05M |
| CashAndCashEquivalents | 8.00M | 6.47M | 5.47M | 17.05M |
| CashFinancial | 8.00M | 6.47M | 5.47M | 17.05M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -29.61M | -33.24M | -34.78M | -34.98M |
| RepaymentOfDebt | -100.00K | -100.00K | -100.00K | -1.92M |
| IssuanceOfDebt | 0.00 | 3.98M | 10.97M | |
| IssuanceOfCapitalStock | 31.91M | 32.71M | 20.46M | 33.58M |
| CapitalExpenditure | -231.00K | -1.68M | -6.00K | |
| InterestPaidSupplementalData | 14.00K | 35.00K | 23.00K | 28.00K |
| EndCashPosition | 8.00M | 6.47M | 5.47M | 17.05M |
| BeginningCashPosition | 6.47M | 5.47M | 17.05M | 8.09M |
| EffectOfExchangeRateChanges | -54.00K | 15.00K | 16.00K | 0.00 |
| ChangesInCash | 1.59M | 985.00K | -11.60M | 8.96M |
| FinancingCashFlow | 31.20M | 34.23M | 23.18M | 43.94M |
| CashFlowFromContinuingFinancingActivities | 31.20M | 34.23M | 23.18M | 43.94M |
| NetOtherFinancingCharges | -608.00K | 380.00K | -1.16M | -731.00K |
| ProceedsFromStockOptionExercised | 0.00 | 1.24M | 0.00 | 2.04M |
| NetPreferredStockIssuance | 0.00 | 611.00K | 0.00 | |
| PreferredStockIssuance | 0.00 | 611.00K | 0.00 | |
| NetCommonStockIssuance | 31.91M | 32.10M | 20.46M | 33.58M |
| CommonStockIssuance | 31.91M | 32.10M | 20.46M | 33.58M |
| NetIssuancePaymentsOfDebt | -100.00K | -100.00K | 3.88M | 9.05M |
| NetLongTermDebtIssuance | -100.00K | -100.00K | 3.88M | 9.05M |
| LongTermDebtPayments | -100.00K | -100.00K | -100.00K | -1.92M |
| LongTermDebtIssuance | 0.00 | 3.98M | 10.97M | |
| InvestingCashFlow | -231.00K | 0.00 | -1.68M | -6.00K |
| CashFlowFromContinuingInvestingActivities | -231.00K | 0.00 | -1.68M | -6.00K |
| NetIntangiblesPurchaseAndSale | -215.00K | 0.00 | -1.60M | 0.00 |
| PurchaseOfIntangibles | -215.00K | 0.00 | -1.60M | 0.00 |
| NetPPEPurchaseAndSale | -16.00K | 0.00 | -77.00K | -6.00K |
| PurchaseOfPPE | -16.00K | 0.00 | -77.00K | -6.00K |
| OperatingCashFlow | -29.38M | -33.24M | -33.10M | -34.97M |
| CashFlowFromContinuingOperatingActivities | -29.38M | -33.24M | -33.10M | -34.97M |
| ChangeInWorkingCapital | -3.01M | -11.10M | -4.43M | 2.27M |
| ChangeInOtherWorkingCapital | 723.00K | |||
| ChangeInOtherCurrentLiabilities | -451.00K | -394.00K | -315.00K | -19.00K |
| ChangeInOtherCurrentAssets | -336.00K | -17.00K | -550.00K | -408.00K |
| ChangeInPayablesAndAccruedExpense | -803.00K | -3.81M | 542.00K | 3.19M |
| ChangeInAccruedExpense | -1.13M | -2.96M | -360.00K | 3.03M |
| ChangeInPayable | 328.00K | -855.00K | 902.00K | 158.00K |
| ChangeInAccountPayable | 328.00K | -855.00K | 902.00K | 158.00K |
| ChangeInPrepaidAssets | -1.51M | -5.01M | -1.56M | -796.00K |
| ChangeInInventory | -1.16M | -2.17M | -2.12M | -2.12M |
| ChangeInReceivables | 526.00K | 298.00K | -421.00K | 2.42M |
| ChangesInAccountReceivables | 440.00K | -88.00K | -170.00K | 2.82M |
| OtherNonCashItems | 283.00K | 13.38M | 12.58M | 5.19M |
| StockBasedCompensation | 1.64M | 2.11M | 3.32M | 3.97M |
| UnrealizedGainLossOnInvestmentSecurities | 9.48M | 5.12M | 21.00K | 1.95M |
| AssetImpairmentCharge | 0.00 | 371.00K | 0.00 | |
| DepreciationAmortizationDepletion | 2.36M | 2.39M | 2.29M | 1.81M |
| DepreciationAndAmortization | 2.36M | 2.39M | 2.29M | 1.81M |
| Depreciation | 2.36M | 2.39M | 2.29M | 1.81M |
| OperatingGainsLosses | -1.11M | -3.65M | 2.19M | 2.44M |
| EarningsLossesFromEquityInvestments | 138.00K | 51.00K | 0.00 | |
| GainLossOnInvestmentSecurities | 1.63M | |||
| NetIncomeFromContinuingOperations | -39.03M | -41.87M | -49.08M | -52.60M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for JAGX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|